Clinical trials: Cirrhosis Due to Hepatitis B
Cirrhosis of Liver Due to Hepatitis B (Disorder)
Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients
The study aims to demonstrate that whether treatment of nucleoside （acid）analogues (NAs) plus pegylated interferon (Peg IFN) α-2b for those NAs treated, low level of HBsAg, hepatitis B related compensatory cirrhosis patients will…
- Trial name
- NCT03969017
- Testing
- pegylated interferon (Peg IFN)α-2b, Nucleoside （acid）analogue (NAs)
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Cirrhosis Due to Hepatitis B, Cirrhosis Due to Hepatitis C
Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis
Carvedilol has been shown to be more potent in decreasing portal hypertension to propranolol. A lot of studies have shown that the imbalance of flora and the progress of portal hypertension are mutually causal.
- Conditions
- Cirrhosis Due to Hepatitis B, Cirrhosis Due to Hepatitis C, Gastroesophageal Varices
- Trial name
- CABER (NCT04543643)
- Testing
- Carvedilol, Berberine
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Tianjin Second People's Hospital
Cirrhosis, Cirrhosis Due to Hepatitis B
Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer
Aim: To use magnetic resonance imaging (MRI) scans without contrast to help improve diagnosis of liver cancer in people who are at increased risk of developing liver cancer.
- Conditions
- Cirrhosis, Cirrhosis Due to Hepatitis B, Cirrhosis and Chronic Liver Disease, Cirrhosis Due to Hepatitis C
- Trial name
- AMULET (NCT06658782)
- Testing
- non contrast enhanced MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- University of Oxford
Cirrhosis Due to Hepatitis B
Study of Human Umbilical Cord Mesenchymal Stem Cell in Patients With Cirrhosis Due to Hepatitis B (Compensation Stage)
There are about 240 million chronic hepatitis B virus (HBV) infected people in the world, and about 2%-5% of compensated cirrhosis patients progress to decompensated cirrhosis patients every year.
- Trial name
- NCT05507762
- Testing
- UC-MSCs, Saline solution
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Renmin Hospital of Wuhan University
Liver Fibrosis
Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls
This trial adopts a single-center, single-dose, open-label, non-randomized, parallel-controlled design. It will be conducted in participants with varying degrees of hepatic impairment, as well as in participants with normal…
- Trial name
- NCT07394309
- Testing
- Hydronidone capsules
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Liver Cirrhoses
Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B
The study aims to evaluate the effect of allogeneic mesenchymal stem cell therapy on patients who suffered from liver cirrhosis caused by Hepatitis B.
- Trial name
- NCT04357600
- Testing
- Allogeneic Umbilical Cord Mesenchymal Stem Cell
- Where
- Indonesia
- Volunteers
- 12 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Hepatitis B Virus Related Cirrhosis
Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV
Liver Cirrhosis is a common pathological consequence of chronic liver disease. Hepatitis B Virus (HBV) is one of most etiologies of Liver cirrhosis in China.
- Trial name
- NCT02241616
- Testing
- Entecavir+Fuzheng Huayu+TCM Granule
- Where
- 20 sites in China
- Volunteers
- 350 people
- Sponsor
- ShuGuang Hospital
Liver Cirrhosis, Chronic Hepatitis C
Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis
Hepatitis C is the leading cause of chronic liver disease and cirrhosis in United States veterans. Cirrhosis is associated with impaired antibody responses and increased risk of bacterial infections.
- Trial name
- NCT01951209
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- David E. Kaplan, MD MSc
Liver Cirrhosis Due to Hepatitis B Virus
Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir
Liver Cirrhosis is a common pathological consequence of chronic liver disease. Hepatitis B Virus (HBV) is one of most etiologies of liver cirrhosis in China.
- Trial name
- NCT02241590
- Testing
- Entecavir + Fuzheng Huayu Tablet
- Where
- 20 sites in China
- Volunteers
- 700 people
- Sponsor
- ShuGuang Hospital
Cirrhosis Due to Hepatitis B
A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis
Entacavir and tenofovir are two first line therapies for chronic hepatitis B. Both agents have been claimed equivalent in treatment, there are no head to head trials available in the literature about there effectiveness in HBV…
- Trial name
- NCT02238860
- Testing
- Entacavir, Tenofovir
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Asian Institute Of Medical Sciences
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN RESCU (NCT05832229)
- Testing
- Rosuvastatin
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis b, Cirrhosis Due to Hepatitis B
The Efficacy and Safety of TAF vs Other NAs in Patients With LVL
Patients with chronic hepatitis B should maximize the inhibition of HBV replication, which could reduce the incidence of liver cancer and liver disease-related complications.
- Trial name
- NCT04501224
- Testing
- Tenofovir alafenamide fumarate, Entecavir or Tenofovir disoproxil fumarate
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Porto-Sinusoidal Vascular Disease, Cirrhosis Due to Hepatitis B
TIPS for Platinum-Related Porto-Sinusoidal Vascular Disease With Variceal Bleeding
Platinum-based compounds are associated with several adverse effects, including Porto-Sinusoidal Vascular Disease (PSVD). Therapeutic strategies for platinum-related PSVD are based on the management of complications seen in…
- Conditions
- Porto-Sinusoidal Vascular Disease, Cirrhosis Due to Hepatitis B, Esophageal Variceal Rebleeding, Gastric Variceal Bleeding
- Trial name
- NCT06635122
- Testing
- Transjugular intrahepatic portosystemic shunt, Endoscopic treatment
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Air Force Military Medical University, China
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Cohort Study
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN-C (NCT05740358)
- Where
- 14 sites in United States
- Volunteers
- 1,222 people
- Sponsor
- Northwestern University